Healthcare Industry News: Patent foramen ovale
News Release - February 6, 2006
NMT Medical's MIST Trial Results to be Presented at the American College of Cardiology Annual Scientific SessionPFO/Migraine Study Outcomes with STARFlex(R) Technology to be Featured at Late-Breaking Clinical Trials Sessions
BOSTON, Feb. 6 (HSMN NewsFeed) -- NMT Medical, Inc. (Nasdaq: NMTI ) announced today that results from its MIST (Migraine Intervention with STARFlex® Technology) trial are scheduled to be presented at the American College of Cardiology's 55th Annual Scientific Session on Monday, March 13, 2006 at 9:00 am (ET).
MIST is the first prospective, randomized, double-blinded study to evaluate the effect of PFO (Patent foramen ovale) closure on migraine headaches. NMT's proprietary PFO closure technology was exclusively used in the study. Data from the multi-center clinical trial will be jointly presented by co-primary investigators Andrew Dowson, MD and Peter Wilmshurst, MD. Dr. Dowson is Director of the King's Headache Service, Kings College Hospital, London. Dr. Wilmshurst is Consultant Cardiologist at Royal Shrewsbury Hospital, Shrewsbury.
President and Chief Executive Officer, John E. Ahern, and Vice President and Chief Financial Officer, Richard E. Davis, along with the co-primary investigators, will hold a conference call with the investment community following the announcement on Monday, March 13, 2006 at 11:30 a.m. (ET).
Those who wish to participate in the conference call should dial (866) 323-7221 or (706) 643-0228 prior to the start of the call. To access the call by telephone, you will need to provide conference ID: 5064691. Individuals who are interested in listening to the live webcast over the Internet should log on to the "Investor Relations" section of NMT Medical's website at http://www.nmtmedical.com prior to the event's broadcast.
About NMT Medical, Inc.
NMT Medical is an advanced medical technology company that designs, develops and markets proprietary implant technologies that allow interventional cardiologists to treat cardiac sources of migraine headaches, stroke and other potential brain attacks through minimally invasive, catheter- based procedures. NMT Medical is investigating the potential connection between a common cardiac defect called a PFO and brain attacks such as migraine headaches, stroke and TIAs. A PFO can allow venous blood, unfiltered and unmanaged by the lungs, to enter the arterial circulation of the brain, possibly triggering a cerebral event or brain attack.
More than 20,000 PFOs have been closed globally with NMT's minimally invasive, catheter-based implant technology.
The prevalence of migraines in the United States is about 10%. Of the 28 million migraine sufferers in America, those who experience aura and have a PFO may represent a three million patient subset. Stroke is the third leading cause of death in the United States and the leading cause of disability in adults. Each year, 750,000 Americans suffer a new or recurrent stroke and 500,000 Americans experience a TIA.
The Company also serves the pediatric interventional cardiologist with a broad range of cardiac septal repair implants delivered with nonsurgical catheter techniques. For more information about NMT Medical, please visit http://www.nmtmedical.com.
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements -- including statements regarding the scheduled presentation of MIST results at the ACC conference, the outcome of the Company's MIST trial, and expansion of the Company's cardiovascular business and market opportunities, including migraines and any other new applications for the Company's technology or products -- involve known and unknown risks, uncertainties or other factors that may cause actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward- looking statements. Factors that may cause such a difference include, but are not limited to, the Company's ability to develop and commercialize new products, a potential delay in the regulatory process with the U.S. Food and Drug Administration and foreign regulatory agencies, as well as risk factors discussed under the heading "Certain Factors That May Affect Future Results" included in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's Annual Report on Form 10-K for the year ended December 31, 2004, Quarterly Report on Form 10-Q for the period ended September 30, 2005, and subsequent filings with the U.S. Securities and Exchange Commission.
Source: NMT Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.